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Juvenile Idiopathic Arthritis (JIA) is the most common cause of chronic arthritis in childhood and adolescents and encompasses
a heterogeneous group of diﬀerent diseases. Due to the promising results of B-cell depleting therapies in rheumatoid arthritis the
role of B-cells in autoimmune diseases has to be discussed in a new context. Additionally, experiments in mouse models have shed
new light on the antibody-independent role of B-cells in the development of autoimmune diseases. In this review we will discuss
the importance of B-cells in the pathogenesis of JIA appraising the question for an immunological basis of B-cell targeted therapy
in JIA.
1.Introduction
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous con-
dition gathering together distinct forms of chronic arthritis
of unknown etiology that begin before the age of sixteen
and persist at least six weeks [1]. The common denominator
is a chronic inﬂammatory process aﬀecting the synovia.
According to the ILAR-criteria, JIA is currently divided into
seven diﬀerent subtypes by means of clinical and laboratory
parameters [2].
WhereasthesystemiconsetformofJIA(soJIA)ischarac-
terized by an exaggerated inﬂammatory cascade of the innate
immune system without evidence of classical autoimmune
features (regarded as “autoinﬂammation”), autoimmune
phenomena (autoreactive T-cells as well as autoantibodies)
can be detected readily in the poly- and oligoarticular
subgroups [3, 4]. Therefore, impingement of immunological
tolerance aﬀecting the adaptive immune system can be
hypothesized in both the latter subgroups. A distinctive
feature of chronic inﬂammatory arthritis is the presence of
synovial lymphocytic inﬁltrates that play a role in disease
pathogenesis by secretion of proinﬂammatory cytokines and
other soluble mediators. Both T- and B-cells are detected
in synovial inﬁltrates from JIA and Rheumatoid Arthritis
(RA) patients. Evidence of autoreactive T-cells as well as
autoantibodies reacting with several tissue autoantigens has
been provided in both diseases [5, 6]. Beside their well-
known function as antibody secreting cells, an antibody-
independent role for B-cells in disease pathogenesis has been
documented by experimental data as well as the promising
results of B-cell depleting therapies in RA [7–9]. Therefore,
B-cells might be a promising cellular target for future
therapeutic options in JIA as well. In this paper, we will focus
on the role of B-cells in the pathogenesis of JIA and discuss
possible therapeutic implication of B-cells as targets in JIA.
2.Autoantibodies
TheroleofB-cellsinautoimmuneandchronicinﬂammatory
diseases has been predominantly viewed from the perspec-
tive as precursors of autoantibody producing plasma cells.
Autoantibodies might be directly involved in tissue damage;
alternatively, the formation of immune complexes might
trigger chronic inﬂammation in a genetically predisposed
individual.
Autoantibodies reacting with diﬀerent tissue autoanti-
gens can be detected in sera of patients with JIA [10–36]. In
parallel to seropositive RA, a distinct group of patients with2 Arthritis
polyarticular onset JIA are characterized by the presence of
rheumatoidfactor(RF)[1,28].TheseadolescentJIApatients
resemble RA patients in terms of clinical as well as immuno-
logical parameters. Besides the presence of RF, antibodies
againstcitrullinatedproteins(ACPA)canbedetectedinthese
patients. In particular, antibodies against cyclic citrullinated
peptide (anti-CCP) as well as against mutated citrullinated
vimentin (anti-MCV) have been documented in the RF
positive polyarticular subgroups of JIA patients, but not in
other subgroups [10–12, 14, 18, 27, 28, 32, 35, 37]. These
autoantibodies yielded higher speciﬁcity in diagnosing RA
and might distinguish a characteristic group of polyarticular
J I Ap a t i e n t sa sw e l l[ 26, 28]. Anti-CCP antibodies seemed
to be associated with a more severe disease progress in RA
patients [38]. However, due to the low frequencies of JIA
patients displaying ACPAs, these observations have not been
replicated for JIA patients. Therefore, testing for ACPAs
should not generally be recommended in the diagnostic
work-up of childhood arthritis but might be relevant for
predicting a severe disease course in a small group of
polyarticular onset JIA patients.
The presence of antinuclear antibodies (ANAs) indicates
loss of tolerance against nuclear autoantigens which is a
hallmark in the oligoarticular onset subgroup of JIA patients
[19, 23, 39]. However, raised titres of ANAs might be present
in the polyarticular subgroup and in psoriatic arthritis as
well [1]. Although frequently found in JIA patients, the
distinct autoantigens of these ANAs are not identiﬁed yet.
Antibodies against histones and nonhistone chromosomal
proteinshavebeendetectedinJIApatients[16,17,20–22,24,
26, 29, 33, 34]. However, the antibody proﬁle seemed to be
highly individual and did not correlate with disease subtype.
At present, there are no autoantibodies against distinct
autoantigens known which could completely explain ANA
reactivity found in JIA patients’ sera. Therefore, ANA testing
is still performed by means of indirect immunoﬂuorescence
on ﬁxed epidermoid larynx carcinoma cells (Hep2-cells),
and eﬀorts to convert ANA testing to ELISA-technique
using recombinant or puriﬁed native nuclear antigens have
brought conﬂicting results [40, 41]. Nevertheless, ANA
testing still has its place in the diagnostic work-up of
childhood arthritis. Several reports have documented the
association between the presence of ANAs and uveitis in
JIA patients [22, 39, 42, 43]. Therefore, testing for ANAs is
recommended in the initial work-up of childhood arthritis
for risk stratiﬁcation of uveitis, and the presence of ANAs
has been suggested as a risk factor in the recommendation
for uveitis screening in JIA patients [42]. However, ANAs
are present in healthy individuals as well and might be
transiently increased during viral or bacterial infections.
Therefore, the validity of ANA testing in diagnosing JIA
is limited due to its low disease speciﬁcity. Besides their
low speciﬁcity in diagnosing JIA per se, ANAs might be
an indicator for a distinct JIA subgroup [39]. By eﬀort to
improve JIA classiﬁcation, it has been suggested to deﬁne
homogeneous subgroups by combining patients with pso-
riatic, oligoarticular, and RF-negative polyarticular arthritis
and exploring the value of variable such as age at onset,
symmetry of arthritis, and ANA status [44]. ANA-positive
patients seem to be relatively homogeneous in terms of early
onset of disease (<6 y/o), predominantly female gender, and
high risk for iridocyclitis and asymmetric, predominantly
oligoarticular JIA [39]. These clinical ﬁndings could be
supported by gene expression analysis which indicated a
B-cell signature in ANA-positive patients with early-onset
JIA [45]. Furthermore, the B-cell signature was present
in patients with early-onset RF-negative polyarticular JIA
as well. In contrast, patients with late onset oligoarticular
or RF-negative polyarticular JIA indicated a myeloid gene
expression signature. Therefore, age at onset rather than
the number of aﬀected joints might hallmark a distinct JIA
subgroupwhichischaracterizedbyalossoftoleranceagainst
nuclear antigens.
Despite the clinical relevance of autoantibody testing in
JIA, the molecular and cellular mechanisms which lead to
loss of immunological tolerance and production of autoan-
tibodies are not understood in detail, but underline the
central role of B-cells in the pathogenesis of JIA [46]. Much
work has been done in characterizing the molecular events
leading to the generation of autoreactive immunoglobulins.
Immunoglobulin diversity is maintained by several molec-
ular processes including the random recombination of V,
D, and J gene segments during the development of B-cells
in the bone marrow. These random recombinations of gene
segments is inevitably linked with generation of autoreactive
immunoglobulins [47]. However, tolerance mechanisms are
in place in order to avoid the generation of autoreac-
tive B-cells in healthy individuals [48]. Besides apoptosis
and anergy, a second round of V(D)J-recombination in
autoreactive B-cells of the bone marrow (receptor editing)
seems to be a powerful mechanism to exclude potential
harmful receptors from the primary B-cell repertoire [49].
A skewed immunoglobulin kappa light chain repertoire
has been detected in na¨ ıve peripheral blood B-cells of JIA
patients by means of single-cell PCR [50]. In particular, the
disturbed kappa immunoglobulin light chain repertoire of
these B cells might be sequels of two molecular processes:
increased events of secondary V(D)J-recombination and
a bias for distinct gene segments during the process of
recombination. Therefore, one might speculate that B-cell
tolerance might be broken by more than one pathogenic
mechanism in JIA B cells. Interestingly, increased events
of secondary V(D)J-recombination were also suggested by
analysing the kappa:lambda ratio in peripheral blood B-cells
of JIA patients [51]. V(D)J-recombination has long been
considered to be restricted to early B-cell precursors in the
bone marrow. However, the observation of B-cells under-
going V(D)J-recombination in secondary lymphoid organs
led to the proposal of receptor diversiﬁcation taking place
in mature activated B-cells (receptor revision) [52, 53]. This
secondary rearrangement might promote autoimmunity by
an uncontrolled creation of autoreactive antibodies. In this
regards it was interesting to observe, that mature peripheral
blood B-cells of JIA patients might have the potential to
perform receptor revision outside the bone marrow [54]. B-
cell tolerance checkpoints during early B-cell development
wereshowntobedefectiveinRApatients[55].Summarizing
the above-mentioned ﬁndings in JIA B-cells, one mightArthritis 3
assume that B-cell tolerance checkpoints might be broken
in JIA as well. However, sophisticated analysis on the level
of individual B-cells should be undertaken to prove this
hypothesis.
3 .B - C ell sA sEf f ec t o rs :I m m un ogl o b ul in
SecretingandAntigenPresentingCells
After being activated, B-cells might diﬀerentiate into
eﬀector cells, which are immunoglobulin producing plas-
mablasts/plasma cells and memory B-cells. B-cell devel-
opment and diﬀerentiation follow in a tightly regulated,
age-dependent way. Disturbed peripheral B-cell homeosta-
sis indicating aberrant activation and diﬀerentiation into
eﬀector B-cells has been shown in several autoimmune
diseases [56, 57]. Flow cytometric analysis of peripheral
blood B-cell populations in JIA patients could discover few
diﬀerences compared with healthy individuals. Expansion of
the minor B-cell subset of CD5+ B-cells has been observed
in oligoarticular and polyarticular JIA [58, 59]. CD5+ B-cells
have long been regarded as the human counterpart of the
murine B-1 B-cells. These B-cells are characterized by the
production of antibodies against bacterial wall components,
but also constitute a subgroup of innate-like lymphocytes
which seem to be enriched for autoreactive immunoglob-
ulins [60]. Whether CD5+ B-cells produce disease-related
autoantibodies in JIA is not elucidated, yet. However, rather
than being an equivalent of B-1 B-cells, CD5+ peripheral
blood B-cells might constitute the so-called pre-na¨ ıve B-cells
[61]. This newly-described population represents a stage of
human B-cell maturation that is before the ﬁnal stage of
negative selection of autoantibody expressing B-cells. This
population is both phenotypically and functional distinct
from both transitional B-cells and na¨ ıve B-cells and also
expresses CD5 [62–64]. Additionally, the CD24++CD38++
transitional B-cell subset seems to be expanded in oligoar-
ticular and polyarticular JIA as well [65]. This disturbed
homeostasis of the very early peripheral B-cells as well as the
skewed kappa light chain repertoire in na¨ ıve B-cells suggests
d e f e c t si nB - c e l ld i ﬀerentiation and possibly a failure of
central B-cell tolerance mechanisms in JIA.
Hypergammaglobulinaemia in active disease, mainly in
patients with oligo- and polyarticular-onset JIA, points to B-
cell hyperactivity and has been correlated with clinical dis-
ease activity [59]. Patients with oligoarticular and polyartic-
ular JIA demonstrated B-cell hyperactivity concomitantly
with increased numbers of circulating HLA-DR+ T-cells and
showed a positive correlation between the proportion of
HLA-DR+ CD4+ T-cells and IgG. These ﬁndings point to
the importance of the interaction between hyperactive T-
cells and B-cells. In contrast, B-cell hyperactivity in patients
with soJIA was not associated with increased numbers
of HLA-DR+ T-cells and underlines again the presumed
diﬀerent immunologic character of soJIA and oligoarticu-
lar/polyarticular JIA.
B-cells may possess their pathogenic function at the site
of inﬂammation as activated eﬀector B-cells. Although the
presence of B-cells in the inﬂamed joint has been well docu-
mented in JIA, the clinical relevance is still a matter of debate
and relatively few data are available on this particular issue
[65, 66]. Lymphocytes diﬀusely inﬁltrate or form organized
aggregates with or without germinal centre like reactions
in the inﬂamed synovium. Those structures resembling
germinal centres of secondary lymphatic tissue (“lymphoid
neogenesis”) have been implicated in aberrant B-cell activa-
tion and diﬀerentiation and were thought to be the site of
tolerance breakdown and autoantibody production [67–70].
In RA, lymphoid neogenesis rather seems to be associated
with the degree of inﬂammation than the presence or local
production of autoantibodies [71, 72]. In JIA the pathogenic
role of lymphoid neogenesis remains unclear. Some data
suggest a higher frequency in ANA-positive JIA patients
[66]. However, synovial ﬂuid plasmablast accumulation and
diﬀerentiationdidnotcorrelatewithserumANAtitresinJIA
patients [Morbach et al., unpublished]. Interestingly, at the
ocular site of inﬂammation, local accumulation of plasma
cells has been observed in JIA-associated uveitis and might
have impact on local antibody production [73].
Besides being precursors of antibody-secreting cells, B-
cells are important antigen-presenting and cytokine produc-
ingcellsregulatingT-helpercelldiﬀerentiation.Additionally,
B-cells are involved in the regulation of lymphoid tissue
structures and neogenesis as well as dendritic cell function
[74]. Antigen presentation, expression of costimulatory
molecules, and secretion of cytokines seem to be the
paramount mechanisms of B-cell pathology in an antibody-
independent context. We and others could demonstrate the
accumulation of activated memory B-cells in the joints of
patients with JIA [65]. These B-cells have up-regulated the
costimulatory molecules CD80 and CD86 and could activate
T-cells in vitro and secrete Th1-polarizing cytokines [Mor-
bach et al., submitted]. Therefore, an antibody-independent
role of B-cells in immunopathology should be suggested
of relevance in human chronic inﬂammatory arthritis of
childhood.
4.B-Cell-Targeting Therapies
In adulthood, the anti-CD20 monoclonal antibody ritux-
imab has been given for refractory RA. The promising results
of these B-cell depleting therapies have provided proof of the
concept that B-cells play a central role in driving chronic
inﬂammation in autoimmune diseases [8]. However, the
use of B-cell depleting therapies has been reported only
anecdotally in JIA patients [75]. Summarizing the data on
B-cell pathophysiology in JIA, one might assume that B-cell
targeting therapies might also be eﬀective in the treatment of
JIA patients. However, since B-cell diﬀerentiation follows an
age-dependent developmental pathway, eﬀects on the adult
B-cell system cannot be directly related to the peculiarities of
the B-cell system in childhood. Additionally, the time point
of B-cell depletion during disease progress might decide
between beneﬁcial or harmful eﬀects [76]. Depletion of B-
cells with regulatory capacities has been suggested to be
responsible for converse eﬀects of B-cell-targeted therapies
[77, 78]. Therefore, B-cell-targeting therapies might be a
promising therapeutic option in the treatment of refractory
JIA. However, depletion of B-cells in the developing B-cell4 Arthritis
system of childhood and adolescents should be addressed
with caution.
5. Summary
Although the appearance of autoantibodies is a common
pattern in JIA, less is known about the potential role of
B-cells in JIA pathogenesis. Overall, the diﬀerential gene
expression and clinical observation patterns that distinguish
early and late onset JIA patients suggest that diﬀerent
pathologic mechanisms may be active depending on the age
of disease onset. B-cell pathology seems to play an important
role in early-onset JIA.
Plasma cells are known to diﬀerentiate and accumulate
at the sites of inﬂammation in JIA patients. However, it
remains unknown whether humoral autoimmunity is the
driving force of tissue destruction or, on the contrary,
might be an epiphenomenon of local inﬂammation. Besides
plasma cells, B-cells might function as antigen presenting
cells and provide costimulation and polarizing cytokines
to the synovial T-cells, thereby amplifying pathogenic T-
cell responses. Therefore, B-cells function as ampliﬁers of
chronic inﬂammation in the disease progress of JIA and
might be a target of future therapies.
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